Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
JANX is expected to report earnings to rise 2.03% to -36 cents per share on May 13
Q1'25
Est.
$-0.37
Q4'24
Beat
by $0.07
Q3'24
Missed
by $0.18
Q2'24
Beat
by $0.20
Q1'24
Beat
by $0.04
The last earnings report on February 27 showed earnings per share of -36 cents, beating the estimate of -42 cents. With 390.46K shares outstanding, the current market capitalization sits at 1.67B.